- Home
- CODA vs IMAB Comparison
CODA vs IMAB Comparison
Compare CODA & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODA
- IMAB
- Stock Information
- Founded
- CODA 1994
- IMAB 2014
- Country
- CODA United States
- IMAB United States
- Employees
- CODA N/A
- IMAB N/A
- Industry
- CODA Industrial Machinery/Components
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CODA Industrials
- IMAB Health Care
- Exchange
- CODA Nasdaq
- IMAB Nasdaq
- Market Cap
- CODA 77.7M
- IMAB 73.9M
- IPO Year
- CODA N/A
- IMAB 2020
- Fundamental
- Price
- CODA $7.47
- IMAB $1.31
- Analyst Decision
- CODA Strong Buy
- IMAB Strong Buy
- Analyst Count
- CODA 1
- IMAB 2
- Target Price
- CODA $11.00
- IMAB $5.50
- AVG Volume (30 Days)
- CODA 16.1K
- IMAB 238.6K
- Earning Date
- CODA 06-11-2025
- IMAB 05-15-2025
- Dividend Yield
- CODA N/A
- IMAB N/A
- EPS Growth
- CODA 61.24
- IMAB N/A
- EPS
- CODA 0.34
- IMAB N/A
- Revenue
- CODA $21,064,685.00
- IMAB N/A
- Revenue This Year
- CODA $11.64
- IMAB N/A
- Revenue Next Year
- CODA $14.53
- IMAB N/A
- P/E Ratio
- CODA $21.91
- IMAB N/A
- Revenue Growth
- CODA 15.63
- IMAB N/A
- 52 Week Low
- CODA $5.76
- IMAB $0.60
- 52 Week High
- CODA $9.89
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- CODA 64.16
- IMAB 76.59
- Support Level
- CODA $7.37
- IMAB $0.90
- Resistance Level
- CODA $7.67
- IMAB $1.47
- Average True Range (ATR)
- CODA 0.27
- IMAB 0.10
- MACD
- CODA 0.06
- IMAB 0.04
- Stochastic Oscillator
- CODA 82.76
- IMAB 74.07
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).